Abstract
This study presents “aUToAntiBody Comprehensive Database (UT-ABCD)”, a proteome-wide catalog of autoantibody profiles in 284 human individuals. The subjects included patients diagnosed with Coronavirus disease 2019 (COVID-19), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), atopic dermatitis (AD), as well as healthy controls (HC). Our investigation employed proteome-wide autoantibody screening (PWAS) that utilizes 13,350 autoantigens displayed on wet protein arrays, covering approximately 90% of the human transcriptome. Our findings demonstrated significant elevation of autoantibody levels in COVID-19, SSc, and SLE patients. Unique sets of disease-specific autoantibodies were identified, highlighting the role of autoantibodies against proteins associated with cytokine signaling in immune systems and viral infection pathways. Employing machine learning, we distinguished COVID-19 cases with high accuracy based on autoantibody profiles, notably identifying antibodies against proteins encoded by BCORP1 and KAT2A as highly specific to COVID-19. Longitudinal analysis revealed dynamic changes in autoantibody levels throughout the course of COVID-19, independent of disease severity. Our research highlights the effectiveness of integrating PWAS and autoantigenomics in exploring immune responses in COVID-19 and other diseases. It provides a deeper understanding of the autoimmunity landscape in human disorders and introduces a new bioresource for further investigation.
Competing Interest Statement
K Yamaguchi, T Okumura, C Ono, Y Kobayashi, A Miya, A Sato, and N Goshima were employed by ProteoBridge Corporation. T Fukasawa and A Yoshizaki belong to the Social Cooperation Program, Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, supported by Japan Cosmetic Association and Japan Federation of Medium and Small Enterprise Organizations. T Okamura belongs to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, supported by Chugai Pharmaceutical Corporation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by The University of Tokyo Ethical Committee (Approval number 0695).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
